Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

The ongoing COVID-19 pandemic has highlighted the dearth of approved drugs to treat viral infections, with only ∼90 FDA approved drugs against human viral pathogens. To identify drugs that can block SARS-CoV-2 replication, extensive drug screening to repurpose approved drugs is underway. Here, we sc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:bioRxiv
Autori principali: Schultz, David C., Johnson, Robert M., Ayyanathan, Kasirajan, Miller, Jesse, Whig, Kanupriya, Kamalia, Brinda, Dittmar, Mark, Weston, Stuart, Hammond, Holly L., Dillen, Carly, Castellana, Lauren, Lee, Jae Seung, Li, Minghua, Lee, Emily, Constant, Samuel, Ferrer, Marc, Thaiss, Christoph A., Frieman, Matthew B., Cherry, Sara
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cold Spring Harbor Laboratory 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8240684/
https://ncbi.nlm.nih.gov/pubmed/34189531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.06.24.449811
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi